Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FBXO11 is a candidate tumor suppressor in the leukemic transformation of myelodysplastic syndrome

6 Oct 2020

Abstract excerpt

Myelodysplastic syndrome (MDS) is a heterogeneous myeloid malignancy characterized by blood cell morphological dysplasia, ineffective clonal hematopoiesis, and risk of transformation to secondary acute myeloid leukemia (sAML). A number of genetic abnormalities have been identified in MDS and sAML, but sensitive sequencing methods can detect these mutations in nearly all healthy individuals by 60 years of age. To...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Lymphoma Diagnosis and Treatment
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33024076
DOI: 10.1038/s41408-020-00362-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FBXO11 is a candidate tumor suppressor in the leukemic transformation of myelodysplastic syndromePMID 33024076Read ↗

Myelodysplastic neoplasm-associated U2AF1 mutations induce host defense defects by compromising neutrophil chemotaxis.Semantic proximity Read ↗

The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromesSemantic proximity Read ↗

Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo.Semantic proximity Read ↗

Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.Semantic proximity Read ↗

Splicing factor mutations in the myelodysplastic syndromes: Role of key aberrantly spliced genes in disease pathophysiology and treatment.Semantic proximity Read ↗

Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.Semantic proximity Read ↗

U2AF1 mutation promotes tumorigenicity through facilitating autophagy flux mediated by FOXO3a activation in myelodysplastic syndromes.Semantic proximity Read ↗

Loss of FBXO9 enhances proteasome activity and promotes aggressiveness in acute myeloid leukemiaSemantic proximity Read ↗

SRSF2 Is Essential for Hematopoiesis, and Its Myelodysplastic Syndrome-Related Mutations Dysregulate Alternative Pre-mRNA Splicing.Semantic proximity Read ↗

Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations.Semantic proximity Read ↗

Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.Semantic proximity Read ↗

SF3B1 mutant myelodysplastic syndrome: Recent advances.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.